Myositis‐specific autoantibodies: an important tool to support diagnosis of myositis

Journal of Internal Medicine - Tập 280 Số 1 - Trang 8-23 - 2016
Zoë Betteridge1, NJ McHugh1,2
1Department of Pharmacy and Pharmacology, University of Bath, Bath, UK
2Royal National Hospital for Rheumatic Disease, Bath, UK

Tóm tắt

Abstract

The idiopathic inflammatory myopathies are characterized by muscle weakness, skin disease and internal organ involvement. Autoimmunity is known to have a role in myositis pathogenesis, and myositis‐specific autoantibodies, targeting important intracellular proteins, are regarded as key biomarkers aiding in the diagnosis of patients. In recent years, a number of novel myositis autoantibodies including anti‐TIF1, anti‐NXP2, anti‐MDA5, anti‐SAE, anti‐HMGCRand anti‐cN1A have been identified in both adult and juvenile patients. These autoantibodies correlate with distinct clinical manifestations and importantly are found in inclusion body, statin‐induced, clinically amyopathic and juvenile groups of myositis patients, previously believed to be mainly autoantibody negative. In this review, we will describe the main myositis‐specific and myositis‐associated autoantibodies and their frequencies and clinical associations across different ages and ethnic groups. We will also discuss preliminary studies investigating correlations between specific myositis autoantibody titres and clinical markers of disease course, collectively demonstrating the utility of myositis autoantibodies as both diagnostic and prognostic markers of disease.

Từ khóa


Tài liệu tham khảo

10.1002/mus.24566

10.1007/s13317-011-0018-8

Phan TG, 2002, Autoantibodies to extractable nuclear antigens: making detection and interpretation more meaningful, Clin Diagn Lab Immunol, 9, 1

10.1007/s12016-013-8387-6

10.3109/s10165-009-0155-3

Kavanaugh A, 2000, Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists, Arch Pathol Lab Med, 124, 71, 10.5858/2000-124-0071-GFCUOT

10.1097/01.bor.0000434664.37880.ac

10.1016/j.jbspin.2006.04.005

10.3109/14397595.2014.896494

10.1093/rheumatology/keq281

10.1016/j.autrev.2014.03.004

10.1016/j.autrev.2007.01.013

10.1186/s13075-015-0573-x

10.1097/MD.0b013e31829d08f9

Plestilova L, 2012, Anti‐PM‐Scl autoantibodies in polymyositis and dermatomyositis, Ann Rheum Dis, 71, 240

10.1111/j.1365-2133.2009.09484.x

10.1093/rheumatology/41.9.1040

10.1097/MD.0b013e31824d9cec

10.1016/j.autrev.2010.09.005

10.1016/j.semarthrit.2011.09.008

10.1186/ar3275

10.1136/annrheumdis-2012-201800

10.1371/journal.pone.0060442

10.1002/art.38270

10.1002/art.22865

10.1080/08916930600622884

10.1371/journal.pone.0120313

10.1016/0090-1229(76)90145-8

10.1002/art.1780280711

10.1186/1471-2474-11-223

10.1186/ar4207

10.1002/art.1780371019

Feldman BM, 1996, Clinical significance of specific autoantibodies in juvenile dermatomyositis, J Rheumatol, 23, 1794

10.1093/rheumatology/kem265

10.1080/08916930400022681

10.1136/ard.2005.040717

10.1093/nar/29.12.2517

10.1002/art.24977

10.1242/dev.001750

10.1074/jbc.M805383200

10.1002/art.24702

10.1097/00005792-199111000-00002

10.1136/ard.2008.097162

10.1016/j.autrev.2014.08.011

10.1016/j.jim.2012.07.019

10.3109/08916934.2012.755958

10.1136/annrheumdis-2012-201736

10.1002/art.22164

10.1093/rheumatology/kel161

Targoff I, 2006, Autoantibodies to transcriptional intermediary factor 1‐gamma (TIF1‐g) in dermatomyositis, Arthritis Rheum, 54, 518

10.1002/art.33403

10.1016/j.jaad.2014.12.009

10.1002/art.38863

10.1084/jem.20041367

10.1002/art.22790

10.1093/rheumatology/kem359

10.1002/art.33379

10.3899/jrheum.090461

Matsuura E, 2012, Two young‐adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1‐gamma, Eur J Dermatol, 22, 668, 10.1684/ejd.2012.1824

10.1093/rheumatology/kes073

10.1136/annrheumdis-2011-200871

Oddis C, 1997, Clinical and serological characterisationof the anti‐MJ antibody in childhood myositis, Arthritis Rheum, 40, 139

Targoff I, 2007, Sera with autoantibodies to the MJ antigen react with NXP2, Arthritis Rheum, 56, 787

10.1002/art.24547

10.1136/annrheumdis-2011-200697

10.1002/art.38093

10.1186/ar3822

Tansley S, 2012, Clinical differences between adult and juvenile dermatomyositis assocaited with anti‐NXP2 autoantibodies, Arthritis Rheum, 64, S229

Shinjo SK, 2013, Update on the treatment of calcinosis in dermatomyositis, Rev Bras Reumatol, 53, 211

10.1016/j.jaad.2012.01.015

10.1093/rheumatology/keu259

10.1002/art.21023

10.1002/art.24621

10.1093/rheumatology/kep375

10.1016/j.jaad.2010.09.016

Betteridge Z, 2012, Clinical phenotypes of Caucasian adult and juvenile dermatomyosits patients with anti‐MDA5 autoantibodies, Arthritis Rheum, 64, S715

10.1002/acr.21992

10.1002/acr.21985

Ceribelli A, 2014, Prevalence and clinical significance of anti‐MDA5 antibodies in European patients with polymyositis/dermatomyositis, Clin Exp Rheumatol, 32, 891

10.1186/ar3547

10.1002/art.34657

10.1016/j.jpeds.2010.11.033

10.1186/ar4600

10.3109/s10165-012-0663-4

10.1093/rheumatology/ker518

10.1093/rheumatology/ker408

10.1073/pnas.83.24.9507

Rouster‐Stevens KA, 2008, Autoantibody to signal recognition particle in African American girls with juvenile polymyositis, J Rheumatol, 35, 927

10.1002/art.1780330908

10.1136/ard.2006.052191

10.1016/j.nmd.2014.01.002

10.1002/art.11484

10.1002/mus.20693

10.1136/jnnp.73.4.420

10.1093/rheumatology/kep027

10.1002/art.30344

10.1093/rheumatology/keu436

10.1002/art.27572

Mammen AL, 2012, Increased frequency of DRB1*11:01 in anti‐hydroxymethylglutaryl‐coenzyme A reductase‐associated autoimmune myopathy, Arthritis Care Res, 64, 1233, 10.1002/acr.21671

10.1212/NXI.0000000000000096

10.1002/art.30156

10.1002/acr.20662

10.1097/MD.0000000000000416

10.1097/MD.0000000000000028

10.1016/j.jneuroim.2012.04.007

10.1371/journal.pone.0020266

Pluk H, 2011, Anti‐Mup44: the first inclusion body myositis‐specific autoantibody, Autoantigens Autoantibodies AutoImmun, 7, 210

10.1002/ana.23822

10.1002/ana.23840

Herbert MK, 2015, Disease specificity of autoantibodies to cytosolic 5’‐nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases, Ann Rheum Dis